Cleerly ISCHEMIA vs qXR-CTR

Tool B (qXR-CTR) offers a broader range of usability features, including annotated X-rays, structured reports in DICOM and JSON, a DICOM viewer with measurement tools, multilingual UI, and mobile/desktop access via the Qure.ai App. Tool A (Cleerly ISCHEMIA) focuses on comprehensive interactive web-based reports and PowerScribe integration, but Tool B's offerings appear more extensive for diverse clinical workflows.

Tool A (Cleerly ISCHEMIA) provides significantly higher clinical value by performing a comprehensive, multi-faceted analysis of CCTA scans, including non-invasive fractional flow reserve (FFR) estimation, coronary plaque characterization, and stenosis severity assessment, which directly aids in personalized diagnosis and treatment planning. It has been validated in multiple clinical trials and demonstrated prognostic utility for major adverse cardiovascular events (MACE). Tool B (qXR-CTR) automates a single measurement (cardiothoracic ratio) from chest X-rays, serving as a diagnostic aid for heart size assessment.

Both tools have opaque pricing, requiring direct contact for details. However, Tool A (Cleerly ISCHEMIA) has a clear value proposition with its dedicated Category I CPTu00ae Code 75580, which provides a defined reimbursement pathway for providers, effective January 1, 2024. This established billing code offers a tangible financial benefit and clarity for adoption that Tool B currently lacks.

While both tools are FDA-cleared, HIPAA compliant, and offer BAAs, Tool B (qXR-CTR) demonstrates stronger enterprise readiness with its flexible deployment options (cloud, on-premise, hybrid) and broad integration capabilities with major PACS vendors via DICOM. Additionally, Tool B explicitly lists comprehensive security features like encryption, RBAC, SSO/SAML, audit logs, and 2FA, making it more adaptable and secure for diverse enterprise IT environments.

Tool A (Cleerly ISCHEMIA) exhibits greater innovation by applying AI to a more complex imaging modality (CCTA) to provide a detailed, quantitative analysis of coronary artery disease, including non-invasive FFR estimation and comprehensive plaque characterization. This goes beyond automating a standard measurement to offer personalized insights for treatment planning and prognostic risk stratification. Tool B automates a more straightforward measurement from chest X-rays.

Tool B (qXR-CTR) clearly wins this dimension by explicitly detailing a comprehensive range of support channels, including email, phone, chat, ticketing, community, and 24x7 availability. It also offers extensive training options such as documentation, webinars, live online, onsite training, and certification, along with a user manual. Tool A has no publicly available information regarding its support channels or documentation.